GEN Exclusives

More »

GEN News Highlights

More »
Apr 26, 2012

Plus Diagnostics to Co-Market MDxHealth’s ConfirmMDx Prostate Cancer Test in the U.S.

  • Plus Diagnostics is to co-market MDxHealth’s ConfirmMDx prostate cancer test in the U.S. Plus is a U.S. anatomic pathology lab offering a range of multispecialty services. It will co-promote the assay through its national network of urologists.

    “The national reach afforded by Plus Diagnostics provides a direct channel into the urology community and will aid in meeting the growing demand for our test,” comments Jan Groen, MDxHealth CEO. ConfirmMDx will be carried out at the firm’s laboratory at Irvine, CA, which achieved CLIA certification by the Centers for Medicare and Medicade in January.

    ConfirmMDx for prostate cancer is a laboratory-developed epigenetic test designed to help identify cancer in men who have undergone a biopsy procedure and are shown to have an elevated PSA level, abnormal DRE, or BPH. The assay effectively represents a tool for assessing the presence or absence of cancer cells in biopsy tissue and identifies which patients won’t need to undergo unnecessary repeat biopsies or excessive screening procedures.

    The firm says the test can detect a validated epigenetic field effect associated with the cancerization process at the DNA level in cells adjacent to cancer foci. This molecular halo around the cancer lesion may not necessarily be detectable under the microscope.  


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Tackling Climate Change

Do you think most companies will respond positively to the People’s Climate March?